| Material . | Method . | Study summary . | Reference . |
|---|---|---|---|
| meningioma—patient samples | RT-PCR | GHR expressed in all samples | (303) |
| meningioma—primary cell culture | GHRA-B2036 treatment | suppressed meningioma cell growth | (303) |
| meningioma—patient-derived xenograft in nude mice | GHRA (pegvisomant) treatment/8 weeks | suppressed in vivo tumor growth | (304) |
| glioma—cell lines | RT-PCR | GHR, IGF1R expressed in all samples | (305) |
| glioma—cell lines and nude mice xenograft | GHRH antagonist treatment | suppressed growth in vitro and in vivo | (306, 307) |
| glioma—patient samples | radioimmunoassay | GH and GHR present in all samples and colocalize | (308) |
| glioblastoma—patient samples | gene expression analysis | GHR expression in 1/3 of samples | (309) |
| glioblastoma—patient-derived cells in culture and nude mice xenograft | cell/tumor growth | endogenous GH production, aggressive growth in vivo | (309) |
| glioblastoma—patient sample | proteomic analysis | enrichment of GH, correlates with patient tumor volume | (310) |
| multiple brain tumor patient samples | IHC for GHR | 73% of craniopharyngiomas, 59% of pituitary adenomas, and 23% in germ cell tumors express GHR | (311) |
| Material . | Method . | Study summary . | Reference . |
|---|---|---|---|
| meningioma—patient samples | RT-PCR | GHR expressed in all samples | (303) |
| meningioma—primary cell culture | GHRA-B2036 treatment | suppressed meningioma cell growth | (303) |
| meningioma—patient-derived xenograft in nude mice | GHRA (pegvisomant) treatment/8 weeks | suppressed in vivo tumor growth | (304) |
| glioma—cell lines | RT-PCR | GHR, IGF1R expressed in all samples | (305) |
| glioma—cell lines and nude mice xenograft | GHRH antagonist treatment | suppressed growth in vitro and in vivo | (306, 307) |
| glioma—patient samples | radioimmunoassay | GH and GHR present in all samples and colocalize | (308) |
| glioblastoma—patient samples | gene expression analysis | GHR expression in 1/3 of samples | (309) |
| glioblastoma—patient-derived cells in culture and nude mice xenograft | cell/tumor growth | endogenous GH production, aggressive growth in vivo | (309) |
| glioblastoma—patient sample | proteomic analysis | enrichment of GH, correlates with patient tumor volume | (310) |
| multiple brain tumor patient samples | IHC for GHR | 73% of craniopharyngiomas, 59% of pituitary adenomas, and 23% in germ cell tumors express GHR | (311) |
Abbreviations: GH, growth hormone; GHR, growth hormone receptor; GHRH, growth hormone releasing hormone; IGF1R, insulin-like growth factor 1 receptor; IHC, immunohistochemistry.
| Material . | Method . | Study summary . | Reference . |
|---|---|---|---|
| meningioma—patient samples | RT-PCR | GHR expressed in all samples | (303) |
| meningioma—primary cell culture | GHRA-B2036 treatment | suppressed meningioma cell growth | (303) |
| meningioma—patient-derived xenograft in nude mice | GHRA (pegvisomant) treatment/8 weeks | suppressed in vivo tumor growth | (304) |
| glioma—cell lines | RT-PCR | GHR, IGF1R expressed in all samples | (305) |
| glioma—cell lines and nude mice xenograft | GHRH antagonist treatment | suppressed growth in vitro and in vivo | (306, 307) |
| glioma—patient samples | radioimmunoassay | GH and GHR present in all samples and colocalize | (308) |
| glioblastoma—patient samples | gene expression analysis | GHR expression in 1/3 of samples | (309) |
| glioblastoma—patient-derived cells in culture and nude mice xenograft | cell/tumor growth | endogenous GH production, aggressive growth in vivo | (309) |
| glioblastoma—patient sample | proteomic analysis | enrichment of GH, correlates with patient tumor volume | (310) |
| multiple brain tumor patient samples | IHC for GHR | 73% of craniopharyngiomas, 59% of pituitary adenomas, and 23% in germ cell tumors express GHR | (311) |
| Material . | Method . | Study summary . | Reference . |
|---|---|---|---|
| meningioma—patient samples | RT-PCR | GHR expressed in all samples | (303) |
| meningioma—primary cell culture | GHRA-B2036 treatment | suppressed meningioma cell growth | (303) |
| meningioma—patient-derived xenograft in nude mice | GHRA (pegvisomant) treatment/8 weeks | suppressed in vivo tumor growth | (304) |
| glioma—cell lines | RT-PCR | GHR, IGF1R expressed in all samples | (305) |
| glioma—cell lines and nude mice xenograft | GHRH antagonist treatment | suppressed growth in vitro and in vivo | (306, 307) |
| glioma—patient samples | radioimmunoassay | GH and GHR present in all samples and colocalize | (308) |
| glioblastoma—patient samples | gene expression analysis | GHR expression in 1/3 of samples | (309) |
| glioblastoma—patient-derived cells in culture and nude mice xenograft | cell/tumor growth | endogenous GH production, aggressive growth in vivo | (309) |
| glioblastoma—patient sample | proteomic analysis | enrichment of GH, correlates with patient tumor volume | (310) |
| multiple brain tumor patient samples | IHC for GHR | 73% of craniopharyngiomas, 59% of pituitary adenomas, and 23% in germ cell tumors express GHR | (311) |
Abbreviations: GH, growth hormone; GHR, growth hormone receptor; GHRH, growth hormone releasing hormone; IGF1R, insulin-like growth factor 1 receptor; IHC, immunohistochemistry.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
